SCHEMBL4701032

SCHEMBL4701032

O=C([C@H]1CCCN(S(=O)(=O)c2ccccc2Cl)C1)N1CCC(c2cccnc2)C1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.53
LMNA P02545 6/20 0.51
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 3/20 0.51
HSD17B10 Q99714 1/20 0.51
SPR P35270 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
MAPT P10636 3/20 0.49
KMT2A Q03164 2/20 0.49
GAA P10253 2/20 0.49
HPGD P15428 2/20 0.49
HSD11B1 P28845 1/20 0.49
MEN1 O00255 1/20 0.49
HTT P42858 1/20 0.49
MAPK1 P28482 2/20 0.47
USP2 O75604 1/20 0.47
PKM P14618 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4701036 1.00 POLB (0.53) POLBLMNAALDH1A1KDM4EHSD17B10
SCHEMBL4882925 0.91 HSD11B1 (0.56) POLBLMNAALDH1A1KDM4EHSD17B10
SCHEMBL4756670 0.91 HSD11B1 (0.56) POLBLMNAALDH1A1KDM4EHSD17B10
SCHEMBL4756664 0.91 HSD11B1 (0.56) POLBLMNAALDH1A1KDM4EHSD17B10
SCHEMBL4703556 0.91 HSD11B1 (0.56) POLBLMNAALDH1A1KDM4EHSD17B10
SCHEMBL4882917 0.91 HSD11B1 (0.56) POLBLMNAALDH1A1KDM4EHSD17B10
SCHEMBL4701055 0.87 LMNA (0.64) LMNAALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL4701050 0.87 LMNA (0.64) LMNAALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL4702147 0.86 MEN1 (0.70) LMNAALDH1A1KDM4EHSD17B10SMN1; SMN2
SCHEMBL4758871 0.86 MEN1 (0.70) LMNAALDH1A1KDM4EHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050288317-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US claimed
EP-1758882-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2008-01-23 EP disclosed
EP-1758882-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-03-07 EP disclosed
WO-2006012173-A1 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-02 WO disclosed
US-20050288317-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288317-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 POLB 2345/4885LMNA 2149/4885ALDH1A1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.